43 results about "Parenteral solutions" patented technology

Packaging materials and containers may be treated with sterilization dosages internally and externally using monochromatic, continuous wave, high-intensity, incoherent light in single and / or multiple light source configurations. The treatment systems and methods preserve physical and performance properties of the packaging / container while achieving a desired level of sterilization. The sterilized materials may be adapted for extended shelf life (ESL) products. The disclosed treatment systems and methods may also be used for sterilization of food and beverage products (either prepackaged or post packaged), medicines, pharmaceuticals, vitamins, infusion products, clinical and / or non-clinical solutions and systems, enteral and / or parenteral solutions and systems, and the like.

System and method for sterilization, using UV light source(s), of products, e.g., polymer-based products, whether positioned within or external to their packaging, using monochromatic, continuous wave, high-intensity, incoherent light in single and / or multiple light source configurations. The treatment system(s) and method(s) may be used for sterilization of alternative products, including, for example, food products such as meat and poultry, enteral and / or parenteral solutions and systems, and the like.

The invention discloses the novel combined coenzyme Q10 parenteral solution, mainly containing the coenzyme Q10 as active component, polyethylene glycol 15-hydroxyl stearate as solubilizing agent and water for injection as solvent. One or more solvents of cosolvent, acidity regulator, osmoregulator and stabilizing agents can be also added. Low hemolyzation, extreme low histamine release and higher physiological tolerance of a novel solubilizing agent Solutol HS 15 adopted by the parenteral solution remarkably improves clinical medication security and the compliance of a patient; and the parenteral solution has the advantages of good stability, longer period of validity, higher medication convenience for a clinician, better storage and stable transportation, higher security for the clinical medication and better compliance of the patient. The parenteral solution also has the advantages of simple preparation technology, simple and convenient quality control and lower production cost, thereby being beneficial to industrialization production.

This invention relates to a novel pharmaceutical composition which may be administered parenterally to a mammal for the production of general anaesthesia, specifically to a limpid, stable, injectable pharmaceutical formulation of 2,6-diisopropylphenol. The formulation comprises 2,6-diisopropylphenol, a compound of the following general formula (I) wherein R1 and R2 can be the same or different and are hydrogen or lower alkyl group containing 1-3 carbons or acetate group and optionally water and / or one or more antioxidants.

The invention provides a method for preparing high-purity beta-Elemene from natural plants containing beta-Elemene such as curcuma zedoary (root tubers or stem tubers of the curcuma zedoary), Cymbopogon citratus (fresh leaves of the Cymbopogon citrates), Solidago virgaurea (roots, stems, leaves, flowers and seeds of the Solidago virgaurea) and the like so as to improve production efficiency from the initial raw materials to the high-purity beta-Elemene and reduce production cost. Compared with the prior art, the method is mainly characterized in that: the roots, stems, leaves, flowers and seeds of the natural plants are taken as raw materials, and volatile oil of specific parts of the natural plants is prepared by methods for extracting different volatile oil, and then is rectified by a rectification method to prepare high-content beta-Elemene; then impurity components are removed by an ethanol extraction method and a silver nitrate complexing extraction method; finally the beta-Elemene with the content between 95.0 and 99.9 percent is prepared by distillation under reduced pressure; and the beta-Elemene not only can be prepared into oral administrative preparations such as emulsion oral liquid, capsules and the like, but also can be prepared into parenteral administrative preparations such as emulsion parenteral solution, injection, cutaneous permeable agents, lung spray preparations, suppositories and the like. The method has novel design of experimental methods, simple instruments and equipment, concise operation steps and obviously shortened operation time, improves production efficiency and is suitable for industrial production.

Disclosed herein are parenteral solutions containing 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline sulfonamide in N,N-dimethylactamide, polyethylene glycol and D5W useful in the treatment of hypertension, heart failure and renal disease leading to edematous states. Also disclosed are methods for preparing such solutions.

The invention relates to a composition containing glucosamine. The active ingredients of the composition are glucosamine or pharmaceutically acceptable salt thereof and lidocaine or pharmaceutically acceptable salt thereof, and the composition provided by the invention can be prepared into an injection, preferably a parenteral solution, more preferably a small-volume injection. The parenteral solution further comprises an antioxidant, a pH regulator and an alkaline solvent. The composition containing glucosamine provided by the invention can be used for overcoming the defects that freeze-drying preparation of glucosamine is long in freeze-drying time, high in energy consumption and not beneficial to production in the prior art and free-dying preparations in the same batch are different in the shape and solubility. Control on the stability of the parenteral solution and related substances is realized, and the side effect caused by degradation products is reduced, so that the safety and stability requirements of the parenteral solution are met. Therefore, the glucosamine parenteral solution provided by the invention can meet industrial production and can be safely and reliably applied to the field of medicine.

The invention relates to an injection preparation which adopts argatroban as an active component. The injection preparation is characterized by: adopting a single optical isomer of the argatroban or a salt of the argatroban or a hydrate of the argatroban as the medicinal active component and adding a plurality of auxiliary materials with specific types and specific ratios to prepare and develop the preparation for the intravenous injection according to a technical means described in the present patent specification. The formulations of the injection preparation comprise powder injection, small volume parenteral solution or large volume parenteral solution.

The invention relates to a method for preparing ceftiofur hydrochloride parenteral solution; the hydrochloride parenteral solution has the characteristics of even distribution and clear and transparent solution. The method comprises the following steps: (1) adding propylene glycol and ceftiofur hydrochloride with a volume equal to 60-70% of the total volume of ceftiofur hydrochloride parenteral solution to be prepared in a thick mixing tank; adding 2-10g ceftiofur hydrochloride for every 100ml of total volume of the ceftiofur hydrochloride parenteral solution; heating to 40-50 DEG C and stirring for rapid dissolving; (2) adding propylene glycol to reach the total volume of the ceftiofur hydrochloride parenteral solution to be prepared and cooling to 20-30 DEG C; (3) adding active carbon, stirring for 15-20 minutes and filtering; and (4) filling and sealing, sterilizing, light check and packing. The invention solves the problems of difficult and uneven injection of the ceftiofur hydrochloride parenteral solution of the existing technology and makes up the defects of easy-layer and inconvenient use of the ceftiofur hydrochloride suspension injection of the existing technology.

An C-acetate preparation method comprises the following steps: adopting methyl magnesium bromide or methyl magnesium chloride as precursor, reacting the precursor with CO2 in a Loop to prepare an intermediate C-acetyl bromine or magnesium chloride adduct; without adopting purification process, injecting N2 and removing tetrahydrofuran (THF), adding water in the mixture, injecting the mixture through integral small columns (C18 small column, SEP-PAK TSCX small column and SEP-PAK TIX small column) in turn for isolation and purification where the intermediate C-acetyl bromine or magnesium chloride hydrolyzes, filtrating by aseptic filter membrane, neutralizing by alkaline solution and obtaining C-AC parenteral solution. The preparation method of the invention has the advantages of the realization of column hydrolysis and purification, fully automatic synthesis, short synthesis time, high radiochemical yield, high radiochemical purity and low production cost.

The present invention relates to use of a milk apoprotein or a mixture thereof to prevent or treat microbial or viral infection of the human or animal body. It is believed that this is achieved by inhibiting adhesion of potential pathogens. More preferably, at least one milk apoprotein or a mixture thereof is administered, simultaneously or sequentially, with either or both of at least one free fatty acid or a mixture thereof or a monoglyceride thereof; and / or at least one organic acid or a salt or ester thereof or a mixture thereof. The active agent(s) may be delivered by means of a pharmaceutically acceptable delivery system which includes parenteral solutions, ointments, eye drops, nasal sprays, intravaginal devices, surgical dressings, medical foods or drinks, oral healthcare formulations and medicaments for mucosal applications.

A process of preparing a stable parenteral solution of a 1,4-dihydropyridine salt, such as nicardipine hydrochloride, in an acidic aqueous medium. The presence of L-arginine in the solution enhances the solubility of the salt, which is poorly soluble in water.An aqueous, injectable isotonic solution at pH about 3.5-3.6 consists essentially of nicardipine hydrochloride, L-arginine, and a sugar alcohol.An improved single pot manufacturing process for obtaining unsymmetrical 1,4-dihydropyridines by using more than one mole equivalent of aldehyde with respect to the other reactants (amino crotonate and acetoacetate ester). The reaction can be conducted in a solvent present at 20 times the amount of any one component.A process for changing one polymorph of nicardipine hydrochloride (Form A) into another (Form B), and a separate process for the reverse (Form B into Form A).

The invention discloses a Chinese materia medica parenteral solution for the treatment of swine fever disease and its preparation methods; it is a kind of pharmaceutical product made of raw materials based on the following weight ratio: heartleaf houttuynia herb 2-6 portions, wild chrysanthemum 2-6 portions, herba solidaginis 2-6 portions, caulis lonicerae 2-6 portions, Bupleurum chinense 0.5-1.5 portions. Its preparation methods is as follows, mix the Chinese materia medica raw materials heartleaf houttuynia herb, wild chrysanthemum, herba solidaginis, caulis lonicerae, Bupleurum chinense pro rate and then soak them, the ratio of the water and raw materials is 3-6:1, after the raw materials is drenched, distill them with the soak, then the physic liquor is got, then put the gruffs into the containers, add 95% alcohol solution the volume of which is twice by that of the gruffs and extract the effective drug component, finally, the injection of the said invention is got after the distilled physic liquor and the extraction physic liquor is mixed together, after sterilization and packing the products is obtained.

The invention discloses olprinone hydrochloric parenteral solution and a method for preparing the same. In the parenteral solution, water-soluble excipient and organic acids serve as pharmaceutical adjuvant. In the parenteral solution in the invention, fewer sorts of pharmaceutical adjuvant are used, the dosage of the pharmaceutical adjuvant organic acids is greatly reduced, and on the basis of guaranteeing the quality of the preparation, the safety of the preparation is greatly improved.

A method for keeping the quality of an aqueous parenteral solution of thrombomodulin which is not in a frozen or freeze-dried state but in a liquid form in storage and distribution, characterized in that the aqueous thrombomodulin solution containing an effective amount of soluble thrombomodulin and a buffer component exhibiting a buffering activity in a pH range of 5 to 7.0 has a pH of 5 to 7.0 and that (a) the aqueous thrombomodulin solution further contains a surfactant and is in a state aseptically filled into a case or (b) the aqueous thrombomodulin solution is the form of a prefilled syringe preparation produced by aseptically filling the thrombomodulin solution into a syringe substantially without any empty space. This method provides for the storage and distribution of an aqueous parenteral solution of thrombomodulin in a liquid state for a prolonged period and makes it possible to provide an aqueous parenteral solution which is excellent in long-term stability and shaking stability and can save the trouble of dissolving in use.

The present invention relates to use of a milk apoprotein or a mixture thereof to prevent or treat microbial or viral infection of the human or animal body. It is believed that this is achieved by inhibiting adhesion of potential pathogens. More preferably, at least one milk apoprotein or a mixture thereof is administered, simultaneously or sequentially, with either or both of at least one free fatty acid or a mixture thereof or a monoglyceride thereof; and / or at least one organic acid or a salt or ester thereof or a mixture thereof. The active agent(s) may be delivered by means of a pharmaceutically acceptable delivery system which includes parenteral solutions, ointments, eye drops, nasal sprays, intravaginal devices, surgical dressings, medical foods or drinks, oral healthcare formulations and medicaments for mucosal applications.

Liquid vancomycin containing compositions having extended shelf life are disclosed. The compositions contain vancomycin or a pharmaceutically acceptable salt thereof, a polyol such as glycerol, and lactic acid or a lactate. The compositions are ready to use and easily transferred into larger parenteral solutions prior to administration to patients in need thereof.

The invention discloses an acehytisine freeze-drying emulsion and a reparation method thereof. The acehytisine freeze-drying emulsion uses the acehytisine as the active component, comprises oil for injection, emulsifier, additive and freeze-drying protective agent generally used in pharmacy and is dispersed into the emulsifier combination solution having a grain diameter ranging from 300 to 400nm after being added with water for injection. Compared with the acehytisine hydrochloride parenteral solution, the invention can realize 1.36 times of AUC and 1.59 times of MRT with half dosage and has equivalent pesticide effect for resisting arrhythmia.

The invention discloses saussurea involucrate nano particles and a preparation method and an application of the prepared saussurea involucrate nano particles. The saussurea involucrate nano particles in the invention is prepared by the following steps: taking oil phase W emulsified particles as the carrier, taking the aqueous solution of the effective component in the saussurea involucrate or the alcohol solvent O as the internal aqueous phase carrying on the oil phase W emulsified particles by stirring at a high speed to form W / O particles, and coating a covering layer of emulsifier outside the W / O particles to form W / O / W multiple emulsion nano particles. Measurements and tests prove that the grain diameter of the saussurea involucrate nano particles in the invention is in a range of 60-800 nm, the average grain diameter is 134.6nm; saussurea involucrate nano particles in the invention have a shape of quasisphere, smooth surface, even size, no bond between particles, high drug-loading rate, good encapsulating rate and releasing effect and stable releasing rate, can be prepared into oral liquid, tablets, various capsules such as soft capsules, hard capsules and microcapsules, and can be prepared into parenteral solution, lotion, embrocation, patch or electuary.

The invention relates to a Chinese traditional compound medicine and the preparative way of it, which is used to treat myocardial ischemia and improve the microcirculation. The medicine is made up with American ginseng and ophiopogonis and the main ingredients are American ginseng diol group saponin, para-panaxsaponin F11, ophiopogonis Steroid saponin and ophiopogonone, of which American ginseng diol group saponin can't be less than 14.848g, while the American ginseng three groups saponin can't be less than 8.016g. The medicine can be made into different dosage forms such as parenteral solution, high-capacity parenteral solution, freeze-drying powder ampul and so on. The administration route is through intravenous injection.

The invention relates to the field of pharmaceutical preparation, in particular to hydrochloric acid boanmycin liposomes and a preparation method thereof. The hydrochloric acid boanmycin liposome comprises the hydrochloric acid boanmycin liposomes, phospholipids, cholesterin, citric acid, and sodium citrate, gradient regulator which respectively have the following mass percent: 0.5-3.0%, 3-30%, 1-10%, 0.5-3%, and 1-5%. The phospholipids is lecithin, double stearoyl phosphatidyl choline (DSPC), dipalmitoyl phosphatidyl choline (DPPC), dioleoyl phosphatidyl choline (DOPC) and the like. The invention is prepared by adopting the PH gradient method. Compared with the prior art, the hydrochloric acid boanmycin liposomes of the invention can reduce dosage, toxic side effect on human body and production cost and has the advantages such as targeting at some specific organs. The hydrochloric acid boanmycin liposomes of the invention can be prepared into parenteral solution or further prepared into freeze-dried powder hydrochloric acid boanmycin liposomes by adding a supporting agent.

The invention discloses nelarabine parenteral solution and a method for preparing the same. In the process for preparing the parenteral solution, temperature is kept at 50 to 90 DEG C at which the yield of the prepared nelarabine parenteral solution is greatly improved, which provides a good illustration for the influence of the temperature on the stability of the solution of basic medicament andpharmaceutical adjuvant in the process for preparing the nelarabine parenteral solution, and the nelarabine parenteral solution prepared at the temperature is of great scientific significance.

Disclosed are methods for alleviating, relieving, inhibiting, and eliminating acute or chronic pain in a patient suffering from such pain by contacting epithelial tissue of the patient with exogenous GABA (gamma-amino butyric acid).The epithelial tissue includes skin, nasal mucosa or membranes and other epithelial tissue such as buccal, palatal, sublingual, rectal, vaginal, thecal and the like. The GABA is supplied in compositions such as water, saline, buffered saline, parenteral solutions, lotions, semi-solids such as, gels, creams, pastes, salves, ointments, solids such as impregnated patches, impregnated rub-on solid compositions from which layers of GABA may be rubbed onto the skin, sublingual pills, suppositories and the like.

The invention relates to an injector core bar component and an injector employed by the component. The core bar component comprises a sealing plug, a sealing plug base, a spring, a push-pull rod (a tail end of the push-pull rod is arranged with a small sealing plug) and an elastic bayonet lock. Under an interaction of the spring and the elastic bayonet lock, the sealing plug base can be steadily combined with the push-pull rod through the compression and bounce of the spring, press and bounce of the elastic bayonet lock and insertion and extraction of the small sealing plug. An effective automatic control on absorption and effluence of parenteral solution can be realized. In the light of an injector nozzle plug (cover), the injector can not be used secondly. The invention not only can automatically control reusage of the injector, but also can provide safety and reliability, rational design, simple structure, convenient operation and low cost, and the invention can be widely popularized.

Disclosed herein are parenteral solutions containing 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline sulfonamide in N,N-dimethylactamide, polyethylene glycol and D5W useful in the treatment of hypertension, heart failure and renal disease leading to edematous states. Also disclosed are methods for preparing such solutions.

The invention relates to a medicinal microcapsule, taking the potassium sodium dehydroandroan drographolide succinate as medicinal active component, which is characterized in that the potassium sodium dehydroandroan drographolide succinate is coated by macromolecular polysaccharide membrane into the microcapsule. The invention also relates to a preparation method for potassium sodium dehydroandroan drographolide succinate injection; the potassium sodium dehydroandroan drographolide succinate is coated by the macromolecular polysaccharide membrane into the microcapsule and then made into the injection. The invention adopts the micro-capsule embedding technique to process the raw materials of the potassium sodium dehydroandroan drographolide succinate, thereby greatly improving the stability of the potassium sodium dehydroandroan drographolide succinate in aqueous solution, ensuring the mass stability of parenteral solution produced and being favorable for storing the product for a long time.

The present invention relates to a pharmaceutical formulation of siponimod which can be administered parenterally. In particular, the present invention relates to a parenteral solution comprising siponimod and a method for preparing said solution.

The invention discloses the novel combined coenzyme Q10 parenteral solution, mainly containing the coenzyme Q10 as active component, polyethylene glycol 15-hydroxyl stearate as solubilizing agent and water for injection as solvent. One or more solvents of cosolvent, acidity regulator, osmoregulator and stabilizing agents can be also added. Low hemolyzation, extreme low histamine release and higher physiological tolerance of a novel solubilizing agent Solutol HS 15 adopted by the parenteral solution remarkably improves clinical medication security and the compliance of a patient; and the parenteral solution has the advantages of good stability, longer period of validity, higher medication convenience for a clinician, better storage and stable transportation, higher security for the clinical medication and better compliance of the patient. The parenteral solution also has the advantages of simple preparation technology, simple and convenient quality control and lower production cost, thereby being beneficial to industrialization production.

The invention relates to the field of pharmaceutical preparation, in particular to hydrochloric acid boanmycin liposomes and a preparation method thereof. The hydrochloric acid boanmycin liposome comprises the hydrochloric acid boanmycin liposomes, phospholipids, cholesterin, citric acid, and sodium citrate, gradient regulator which respectively have the following mass percent: 0.5-3.0%, 3-30%, 1-10%, 0.5-3%, and 1-5%. The phospholipids is lecithin, double stearoyl phosphatidyl choline (DSPC), dipalmitoyl phosphatidyl choline (DPPC), dioleoyl phosphatidyl choline (DOPC) and the like. The invention is prepared by adopting the PH gradient method. Compared with the prior art, the hydrochloric acid boanmycin liposomes of the invention can reduce dosage, toxic side effect on human body and production cost and has the advantages such as targeting at some specific organs. The hydrochloric acid boanmycin liposomes of the invention can be prepared into parenteral solution or further prepared into freeze-dried powder hydrochloric acid boanmycin liposomes by adding a supporting agent.